SHEL.UK

2,925.5

-0.39%↓

BP

466.5

-2.42%↓

SHEL.UK

2,925.5

-0.39%↓

BP

466.5

-2.42%↓

SHEL.UK

2,925.5

-0.39%↓

BP

466.5

-2.42%↓

SHEL.UK

2,925.5

-0.39%↓

BP

466.5

-2.42%↓

SHEL.UK

2,925.5

-0.39%↓

BP

466.5

-2.42%↓

Search

Smith & Nephew PLC

Gesloten

1,334 1.48

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

1334

Max

1339.5

Belangrijke statistieken

By Trading Economics

Inkomsten

296M

Verkoop

3B

K/W

Sectorgemiddelde

32.354

48.535

EPS

0.429

Dividendrendement

2.89

Winstmarge

9.895

Werknemers

17,000

EBITDA

723M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+11.53% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

2.89%

3.96%

Volgende Winsten

2 mrt 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

11B

Vorige openingsprijs

1332.52

Vorige sluitingsprijs

1334

Smith & Nephew PLC Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

20 feb 2026, 17:37 UTC

Acquisities, Fusies, Overnames

Paramount Regulatory Waiting Period for Warner Bid Expires -- Update

20 feb 2026, 16:18 UTC

Belangrijke Marktbewegers

Footwear Stocks Rise After Supreme Court Strikes Down Tariffs

20 feb 2026, 23:12 UTC

Acquisities, Fusies, Overnames

FERC Authorizes TXNM Energy Acquisition by Blackstone Infrastructure

20 feb 2026, 22:12 UTC

Winsten

Equinox Gold: Announces Filing of 2025 Audited Fincl Statements

20 feb 2026, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

20 feb 2026, 21:50 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

20 feb 2026, 21:23 UTC

Winsten

These Stocks Are Today's Movers: Grail, Corning, Comfort Systems USA, Opendoor, Akamai, Chemours, and More -- Barrons.com

20 feb 2026, 21:20 UTC

Marktinformatie

Century Aluminum Backs Trump's Tariffs After SCOTUS Ruling -- Market Talk

20 feb 2026, 21:01 UTC

Acquisities, Fusies, Overnames

Want to Win the Warner Bros. Discovery Takeover Battle? 'Walk Away Now.' -- Barrons.com

20 feb 2026, 20:38 UTC

Marktinformatie

U.S. Natural Gas Gains Ahead of Chilly Weekend -- Market Talk

20 feb 2026, 20:17 UTC

Marktinformatie

Oil Futures Mixed As Market Awaits U.S.-Iran Moves -- Market Talk

20 feb 2026, 20:11 UTC

Marktinformatie

Traders Await Word on USMCA Exemption For Trump's Global 10% Tariff -- Market Talk

20 feb 2026, 19:59 UTC

Marktinformatie

U.S. Tariff Ruling Could Make Things Worse for Mexico -- Market Talk

20 feb 2026, 19:58 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Netflix Seen as Not Needing Warner Bros. Deal -- Market Talk

20 feb 2026, 19:49 UTC

Marktinformatie

Mexico's Revised 4Q GDP Expected to Confirm Pick-Up -- Market Talk

20 feb 2026, 19:09 UTC

Marktinformatie

Precious Metals Settle Higher After Tariff Ruling -- Market Talk

20 feb 2026, 19:00 UTC

Marktinformatie

U.S. Oil, Gas Rig Counts Unchanged on Week -- Market Talk

20 feb 2026, 18:28 UTC

Marktinformatie

Ontario Premier Warns Fight Against U.S. Tariffs Isn't Over -- Market Talk

20 feb 2026, 18:20 UTC

Marktinformatie

Tariff Ruling Seen Positive for Some Retailers, Mixed for Others -- Market Talk

20 feb 2026, 18:05 UTC

Marktinformatie

Market Talk Roundup: Latest on U.S. Politics

20 feb 2026, 18:04 UTC

Marktinformatie

Trade Uncertainty in Canada to Remain Until USMCA Resolved -- Market Talk

20 feb 2026, 17:38 UTC

Marktinformatie

Canada's Small Firms Look Toward Increased U.S. Tariff Opposition -- Market Talk

20 feb 2026, 17:24 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

20 feb 2026, 17:24 UTC

Marktinformatie

Correction to Treasury Yields Fall Market Talk

20 feb 2026, 17:20 UTC

Marktinformatie

Financial Services Roundup: Market Talk

20 feb 2026, 16:53 UTC

Marktinformatie

Market Talk Roundup: Latest on U.S. Politics

20 feb 2026, 16:53 UTC

Marktinformatie

Canada Dollar Steady, Market Focus on USMCA Review -- Market Talk

20 feb 2026, 16:45 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

20 feb 2026, 16:45 UTC

Marktinformatie

U.K. Public Finances Supportive of Gilts in Near-Term -- Market Talk

20 feb 2026, 16:40 UTC

Marktinformatie

Trade Threats Facing Canada Not Removed by Supreme Court's Ruling -- Market Talk

Peer Vergelijking

Prijswijziging

Smith & Nephew PLC Prognose

Koersdoel

By TipRanks

11.53% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 1,490.57 GBX  11.53%

Hoogste 1,650 GBX

Laagste 1,290 GBX

Gebaseerd op 7 Wall Street-analisten die 12-maands prijsdoelen bieden voor Smith & Nephew PLC - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

7 ratings

5

Buy

2

Hold

0

Sell

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Smith & Nephew PLC

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
help-icon Live chat